Figure 3.

Menin inhibition suppresses the expression of NUP98 fusion target genes. Data were presented as mean (±SD). (A) qPCR results showing significant downregulation of NUP98 fusion target genes including HOXA7-10, (B) CDK6, (E) MEF2C, IGF2BP2, and PBX3 in NUP98-r primary AML samples upon treatment with revumenib (250 nM). (B) Suppression of CDK6 after 14 days of treatment was confirmed at protein level by western blot. (C, D, and F) qPCR results showing expression of MEIS1 and FLT3 after 7 days of treatment. (G) FLT3-ITD expression was downregulated after Menin inhibition as measured by qPCR with ITD-specific primers 1 week after treatment. (H and I) Dose-response curves of patient-derived NUP98::NSD1 (FLT3-ITD+) and RUNX1::ETO AML cells treated with gilteitinib, revumenib, or their combination. Dashed line represents IC₅₀ value. AML = acute myeloid leukemia; qPCR = quantitative PCR.